Clinical Trials and Studies
Some clinical trials have suspended enrollment until further notice due to COVID-19 considerations.
Blood Disorders and Hematologic Cancers
- AB-101 with or without Rituximab for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Assessing the Anti-Tumor Activity and Safety of REGN1979 in Patients with Relapsed or Refractory Follicular Lymphoma
- Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients (VICD)
- CGT9486 Treatment for Advanced Systemic Mastocytosis
- Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease Treatment Study
- Drug Treatment Study for Children with Hemophilia A
- Drug Treatment Study for High Grade B-Cell Lymphomas
- Evaluation of Pediatric Palliative Inpatient Process
- Health Literacy and Numeracy in Adolescent Patients with Hemophilia A and B Study
- Hemophilia A or B Treatment Study
- Hemophilia A Treatment Study
- Luspatercept versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis
- Mantle Cell Lymphoma Treatment Study
- Molecular and Clinical Biology of von Willebrand Disease Study
- National Registry of All Persons with Bleeding and Clotting Disorders
- Newly Diagnosed T-Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma Treatment Study
- Public Health Surveillance for the Prevention of Complications of Bleeding and Clotting Disorders
- Relapsed or Refractory Follicular Lymphoma Treatment Study
- Study for Patients with Acute Myelogenous Leukemia
- Study for Patients with Acute Myeloid Leukemia
- Study for Patients with Non-Advanced Systemic Mastocytosis
- Study of Biomarkers in Hemophilic Arthropathy
- Study of Hepatitis C Virus Outcomes After Treatment in Patients with Bleeding Disorders
- Study Treating Patients With High-Risk Smoldering Myeloma
- Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
- The National Myelodysplastic Syndromes Study
- Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma Study
- Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Study
- Treatment Study for Children with Hemophilia B
- Treatment Study for Newly Diagnosed High Risk B-Lymphoblastic Leukemia in Patients with Ph-like TKI Sensitive Mutations
- Treatment Study for Older Patients with Acute Lymphoblastic Leukemia
- Treatment Study for Patients with Localized Central Nervous System Germ Cell Tumors
- Treatment Study for Patients with Newly Diagnosed B-Lymphoblastic Leukemia or B-Lineage Lymphoblastic Lymphoma
- Treatment Study for Pediatric Patients with Hemophilia A
- Treatment Study for Subjects with Severe Hemophilia A or B
- Treatment Study for Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia